NANOBIOTIX will begin a pre-clinical collaboration with Providence Cancer Institute to study Nanobiotix’s lead product, NBTXR3, a first-in-class nanoparticle designed for direct injection into cancerous tumors and activation by radiotherapy.   The collaboration with Providence Cancer Institute aims to provide essential preclinical data on the ability of NBTXR3 activated by radiotherapy to induce an antitumoral immune response.    Marka R. Crittenden, M.D., Ph.D., radiation ...